06/11/2020 - General information
Each November, the Movember Foundation encourages men from all over the world to grow a moustache to raise awareness and funds for men's health research. The Health Services Research Group at the Hospital del Mar Medical Research Institute (IMIM) is the Spanish coordinator for an international initiative funded by this foundation since 2017. The project, entitled "TrueNTH Global Registry- Prostate Cancer Outcomes", focuses on men diagnosed with localised prostate cancer and has the overarching aim of significantly improving the quality of care, and to leverage existing infrastructures and relationships to build success in this research area. During the last four years, nine countries have prospectively collected data from patients to create a joint dataset, expected to include information of more than10,000 patients. As part of this international registry, 25 Spanish sites are monitoring almost 700 patients so far.
Més informació "Movember: researching how to improve quality of life after prostate cancer"
05/11/2020 - General information
The ICOD (Improving Cognition in Down Syndrome) project is being coordinated by the Integrated Pharmacology and Systems Neuroscience Research Group, led by Dr. Rafael de la Torre. It will trial a new therapy to treat cognitive deficits in Down Syndrome sufferers. Six institutions from Spain, France and Italy are taking part. A project led by the Hospital del Mar Medical Research Institute (IMIM), has received a six million euro development grant from the European Commission. The Improving Cognition in Down Syndrome (ICOD) project was one of 75 projects selected within the European Union's Horizon 2020 research and innovation programme. Only nine projects coordinated by Catalan organisations will benefit from these grants, in the last year they are being awarded.
17/10/2020 - General information
The PRBB and its centres are preparing the next edition of the Open Day. As always, we will be holding our science outreach party for the whole family in October, organised with the support of the park's volunteers. But everything else will be different! The current situation means we are unable to organise a face-to-face celebration, so on this occasion our Open Day events will be 100% virtual. And we have a week full of activities to enjoy from home, with your family and friends or at your educational centre.
Més informació "Open Day at the PRBB - From 26th to 31st October"
16/10/2020 - General information
Dr Robert Güerri, section chief of the Infectious Diseases Service at Hospital del Mar and a researcher in the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute (IMIM), has received a Young Researcher Award from the SI 2020 Symposium, organised by the pharmaceutical company Janssen. The aim of this initiative is to promote the investigative work of young researchers, whose careers have made significant scientific and technical contributions in the field of HIV. The symposium, which should have been held in March, had to be cancelled due to the COVID-19 pandemic.
Més informació "SI 2020 Symposium Young Researcher Award presented to Dr. Robert Güerri"
02/10/2020 - General information
Benign breast diseases (BBD), which are non-cancerous disorders of the breast, such as lumps, are known to increase the chances of subsequent breast cancer. Now a team of Hospital del Mar researchers have found that the way BBD is detected as part of a national screening programme is an indication of which are more likely to become cancerous. The findings from a team led by Dr. Xavier Castells, head of the epidemiology department at the Hospital del Mar and researcher of the Epidemiology and Evaluation research group at the Hospital del Mar Medical Research Institute (IMIM), was presented at the 12th European Breast Cancer Conference on Saturday 3rd. BBD detected on the first occasion a woman attends for breast screening (usually at the age of 50 in Spain and many other European countries with national screening programmes) is classified as "prevalent" BBD, whereas those detected on subsequent visits, which occur every two years in Spain, are classified as "incident" BBD
01/10/2020 - General information
Each year, around 20 million European citizens are affected from depression. Depression is a serious illness which impacts on all aspects of life, including work. While Small and Medium Sized enterprises particularly face substantial economic losses due to the global impact of COVID-19, the MENTUPP consortium anticipates, that capacities for mental health promotion and provision in Small and Medium Enterprises (SMEs) will be even more limited in the future. A second COVID-19 wave might further impact negatively on people affected by depression. This is why action on occupational mental health is urgently needed. Resources for Small and Medium Sized Enterprises "Limited capacities for mental health promotion and provision of adequate occupational mental health programmes for employees are a concern shared by most decision-makers in Small and Medium Sized Enterprises (SMEs)", says Prof. Ella Arensman, Coordinator of the MENTUPP project. In the EU, these businesses contribute to more than 90% of the economy. Particularly, SMEs in the construction, healthcare and Information and Communications Technology (ICT) sectors have been associated with higher risk of mental health difficulties compared to other sectors. COVID-19 has significant short-term and long-term effects on the mental health people working in these sectors.
Més informació "EU-funded Mental Health Promotion and Intervention in Occupational Settings"
03/08/2020 - General information
The Innovation Radar, a European Commission initiative to identify high potential innovations and innovators in EU-funded research and innovation framework programmes, has selected two innovations developed by the GRIB in the project eTRANSAFE to be included on the Innovation Radar platform: Preclinical text mining solution for treatment response Advanced in silico modelling to predict toxicity These innovations, stemming from the project work, have been classified by the Innovation Radar as Exploring innovations in the early phases of technological readiness and have been published on the EU-funded innovations website on July 20th 2020, thus joining the 3600+ EU-funded innovations already showcased on the platform.
30/06/2020 - General information
The successful projects are "Obtaining antioxidant active substances from the carob pod and validating their therapeutic potential", which involves the company Euronutra, the IBIMA (Malaga Biomedical Research Institute), the IMIM (Hospital del Mar Medical Research Institute), and the CRG (Centre for Genomic Regulation); and the project "Development of a new therapy for Fragile X syndrome", in which the company Connecta Therapeutics, the IMIM, and the CRG are participating. The Spanish Innovation Agency call for these grants is part of the State Plan for Scientific and Technical Research and Innovation 2017-2020. The goal is to finance cooperative projects between companies and research bodies in order to carry out joint R&D projects that are close to the market and that, due to their subject matter, are aligned with the priorities established in the challenges of the State R&D Programme Oriented to the Challenges of Society. This year's call has a budget of 260 million euros and one of the requirements is that the coordinator applying for the grant must be a company.
29/06/2020 - General information
This month Sifted, the technology magazine of the Financial Times, has contacted various experts in the technology industry and in analyzing data on investments, has concluded that the Spanish entrepreneurial ecosystem has high quality healthtech startups, ranging from drug discovery to novel virtual reality therapies. In its latest edition, Sifted has published a list of the top healthcare start-ups in Spain, including Chemotargets, the IMIM's spin-off founded in 2006 by Dr. Jordi Mestres, coordinator of the Systems Pharmacology research group at IMIM. Chemotargets is a company that offers state-of-the-art methodologies with predictive capabilities that allow the pharmaceutical and biotechnology industry to accelerate the design and optimization of drug candidates and improve cost efficiency and safety. Its CLARITY® platform covers the entire field of drug discovery and development, from the de novo design of molecules for new targets to pharmacovigilance in the drug market stage.
25/06/2020 - General information
Dr. Ferran Sanz, Dra. Laura Furlong and Dr. Baldo Oliva of the IMIM Biomedical Informatics Research Program, participate in the Disc4All project: Training network to advance integrated computational simulations in translational medicine, applied to intervertebral disc degeneration, coordinated by Jérôme Noailly, principal investigator in the Biomechanics and Mechanobiology research area at BCN MedTech of UPF. It is one of the ten selected projects in Catalonia as an Innovative Training Network (ITN) Marie Sklodowska-Curie, in the European Commission's ITN MSC Actions call. The European innovative training networks (ITN) aim to train a new generation of researchers in their early stages who are creative, enterprising and innovative, capable of dealing with the challenges of the future and turn knowledge and ideas into products and services with an economic and a social benefit.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
